

BSP Antibiogram 2023

GRAM NEGATIVE		ANTIBIOTICS															
1/1/2023-12/31/2023		Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin ^(b)	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE																
<i>Enterobacter cloacae</i> complex	63	•	•	•	97	•	97	91	100	95	99	41	•	85	98	90	
<i>Escherichia coli</i>	883	83	49	81	93	88	73	99	94	71	100	96	96	77	93	77	
<i>Klebsiella pneumoniae</i>	198	90	0	85	89	88	80	99	94	75	100	28	95	73	89	82	
<i>Proteus mirabilis</i>	118	84	66	86	99	95	69	100	94	69	99	0	100	0	98	70	
<i>Pseudomonas aeruginosa</i> ^(b)	186				92		82			73	89		95		97		

GRAM POSITIVE		ANTIBIOTICS									
1/1/2023-12/31/2023		Number tested	Ampicillin	Clindamycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE										
<i>Enterococcus faecalis</i>	174	99		78	99	99		27			97
<i>Staphylococcus aureus</i> , ALL	235		66		100		60	88	90	100	
MRSA only	93		63		100		0	86	87	100	
MSSA only	142		70		100		100	90	93	100	
<i>Staphylococcus epidermidis</i>	73		63		100		36	72	55	100	

- 85-100% Susceptible
- 60-84% Susceptible
- <60% Susceptible
- Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated
- Shaded boxes indicate organism/antimicrobial combinates not tested routinely
- Denotes manufacturer reporting limitation

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints lowered for Enteroabacterales and *Pseudomonas aeruginosa* in 2023. Gentamicin is no longer a reliable treatment option for *Pseudomonas aeruginosa*.